Lung cancer detection by screening - Presenting circulating miRNAs as a promising next generation biomarker breakthrough

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 4, 2013, Pages 2167-2172

  Ramshankar, Vijayalakshmi ^a   Krishnamurthy, Arvind ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

Circulating miRNA; Early stage lung cancers; Lung cancer screening; Plasma miRNA; Serum miRNA

Indexed keywords

EID: 84880302597     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.4.2167     Document Type: Short Survey

References (45)

1. Aberle DR, Adams AM, Berg CD, et al (2011). National lung screening trial research team reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 365, 395-409.
2. Adriano MP, Sandro MP, Matteo Giaj-Levra, et al (2012). Clinical implications and added costs of incidental findings in an early detection study of lung cancer by using lowdose spiral computed tomography. Clinical Lung Cancer, 14, 139-48.
3. Avila-Moreno F, Urrea F, Ortiz-Quintero B (2011). MicroRNAs in diagnosis and prognosis in lung cancer. Rev Invest Clin, 63, 516-35.
4. Bach PB, Jett JR, Pastorino U, et al (2007). Tockman MS, Swensen SJ, Begg CB: computed tomography screening and lung cancer, JAMA, 297, 953-61.
5. Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33.
6. Bellomi M, Rampinelli C, Funicelli L, Veronesi G (2006). Screening for lung cancer. Cancer Imaging, 6, 9-12.
7. Bianch F, Nicassio1y F, Marzi1 M, et al (2011). A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Med, 3, 495-503.
8. Boeri M, Verri C, Conte D, et al (2011). MicroRNA signatures in tissues and cancer. Cancer Imaging, 6, 9-12.
9. Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006.
10. Cortez MA, Calin GA (2009). MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther, 9, 703-711
11. Crowell RE, Goetz T, Wiggins C, et al (2007). Regional disparities in treatment and survival of early stage non-small cell lung cancer. Ethn Dis, 17, 358-64.
12. Deiderich S, Lentschig L, Overbeck O, et al (2001). Detection of pulomonary nodules at spiral CT: comparison of maximum intensity projection sliding slabs and single image reporting. Eur J Radiol 11, 1345-50. detected lung cancer. Proc Natl Acad Sci USA, 108, 3713-8.
13. Foss KM, Sima C, Ugolini D, et al (2011). miR-1254 and miR- 574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol, 6, 482-8.
14. Heneghan HM, Miller N, Kerin MJ (2010). Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol, 28, 573-4.
15. Hennessey PT, Sanford T, Choudhary A, et al (2012). Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One, 7, 32307.
16. Henschke CI, Yankelevitz DF, Libby DM (2006). Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med, 355, 1763-71.
17. Henschke CI, Yip R, Yankelevitz DF, Miettinen OS (2006). Computed tomography screening for lung cancer : prospects of surviving competing causes of death. Clin Lung Cancer, 7, 323-5.
18. Hu Z, Chen X, Zhao Y (2010). Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol, 28, 1721-6.
19. Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.
20. Iorio MV, Croce CM (2009). MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol, 27, 5848-56.
21. Jemal A, Bray F, Melissa M, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
22. Kaneko M, Eguchi K, Ohmatsu H, et al (1996). Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology, 201, 798-802.
23. Keller A, Leidinger P, Gislefoss R, et al (2011). Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA biology, 8, 506-16.
24. Kloosterman WP, Plasterk RH (2006). The diverse functions of microRNAs in animal development and disease. Dev Cell, 11, 441-50.
25. Krishnamurthy A, Vijayalakshmi R, Gadigi V, et al (2012). The relevance of non-smoking associated lung cancer in India: A Single centre experience. Ind J Cancer, 49, 82-8.
26. Le HB, Zhu WY, Chen DD, et al (2012). Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and postoperative lung carcinoma patients. Med Oncol, 29, 3190-7.
27. Miettinen OS (2000). Screening for lung cancer: can it be costeffective? CMAJ, 162, 1431-6.
28. Mitchell PS, Parkin RK, Kroh EM, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 105, 10513-8.
29. Ou SH, Ziogas A, Zell JA (2009). Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol, 4, 37-43.
30. Rabinowits G, Gerçel-Taylor C, Day JM, et al (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer, 10, 42-6.
31. Shen J, Todd NW, Zhang H, et al (2011) Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest, 91, 579-87.
32. Sone S, Li F, Yang ZG, et al (2001). Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer, 84, 25-32
33. Sone S, Takashima S, Li F, et al (1998). Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet, 351, 1242-5.
34. Stefani G, Slack FJ (2008). Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol, 9, 219-30.
35. Swaminathan R, Shantha V, Ferley J, et al (2011). Trends in cancer incidence in Chennai city (1982-2006) and statewide predictions of future burden in Tamilnadu (2007-16). Nat Med J India, 24, 72-7.
36. Tsujiura M, Ichikawa D, Komatsu S, et al (2010). Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer, 102, 1174-9.
37. Vasudevan S, Tong Y, Steitz JA (2007). Switching from repression to activation: microRNAs can up-regulate translation. Science, 318, 1931-4.
38. Wei J, Gao W, Zhu CJ, et al (2011). Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer, 30, 407-14.
39. Welch HG, Black WC (2010). Overdiagnosis in cancer. J Natl Cancer Inst, 102, 605-13.
40. Welch HG, Woloshin S, Schwartz LM, et al (2007). Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med, 167, 2289-95.
41. Wiener RS, Schwartz LM, Woloshin S, et al (2011). Populationbased risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med, 155, 137-44.
42. Xie Y, Todd NW, Liu Z (2010). Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer, 67, 170-6.
43. Xu P, Guo M, Hay BA (2004). MicroRNAs and the regulation of cell death. Trends Genet, 20, 617-24.
44. Yuxia M, Zhennan T, Wei Z (2012). Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol, 138, 2045-50.
45. Zheng D, Haddadin S, Yong Wang (2011). Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol, 4, 575-86.